Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MRK Merck & Co
105.380-1.490-1.39%
Close
01/27 16:00 ET
105.300-0.080-0.08%
Post Mkt Price 01/27 19:41 ET
High
106.680
Open
106.210
Turnover
822.61M
Low
105.110
Pre Close
106.870
Volume
7.78M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.73
Amazon, Apple, Alphabet Headline Another Busy Earnings Week -- WSJ
By Sabela Ojea Apple Inc., Amazon.com Inc., Meta Platforms Inc. and Alphabet Inc. report earnings in the coming week, four of the many companies providing quarterly updates as layoffs and slowing gro
Preview -- Barron's
Monday 1/30 Franklin Resources, GE HealthCare Technologies, and NXP Semiconductors report quarterly results. Tuesday 1/31 Advanced Micro Devices, Amgen, Caterpillar, Chubb, Edwards Lifesciences, El
Merck & Co. Inc. Stock Falls Friday, Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Merck & Co. Inc. (MRK) slid 1.39% to $105.38 Friday, on what proved to be an all-around pos
Bristol Myers Wins EU Backing to Expand Label for Anemia Therapy
Merck Adds Another Arrow to Keytruda US Quiver -- Market Talk
0712 ET - Merck gets FDA approval for expanded use of its blockbuster cancer drug Keytruda as adjuvant treatment in certain patients with non-small cell lung cancer, or NSCLC. The new FDA nod covers K
Merck's Keytruda Approved by FDA for Non-small Cell Lung Cancer Treatment
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSC
Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs
10:26 PM EST, 01/26/2023 (MT Newswires) -- Merck & Co.'s (MRK.PA) animal health division secured the US Food and Drug Administration's approval for the expanded use of Bravecto Chews for Dogs in treat
Merck's Keytruda Approved as Adjuvant Therapy for Non-small Cell Lung Cancer
Company Overview
More
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
CEO： Mr. Robert M. Davis
Market： NYSE
Listing Date： 05/15/1946
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet